Nicole Perry Biography and Net Worth

Nicole D. Perry is Vice President - Finance of the Company. Ms. Perry also served as Vice President of Finance at Revon. From August 2000 to April 2015, Ms. Perry worked as an independent consultant providing services to clients primarily in the areas of financial reporting, internal control compliance and as a liaison with external accountants, bankers and legal counsel. Prior to having her consulting practice, Ms. Perry worked in the audit practices of PricewaterhouseCoopers and Deloitte. Ms. Perry is a Certified Public Accountant and received her B.B.A. in accounting, with distinction, from the University of Oklahoma.

What is Nicole D. Perry's net worth?: The estimated net worth of Nicole D. Perry is at least $277,907.91 as of June 11th, 2021. Ms. Perry owns 5,847 shares of Apellis Pharmaceuticals stock worth more than $277,908 as of April 20th. This net worth evaluation does not reflect any other investments that Ms. Perry may own. Learn More about Nicole D. Perry's net worth.
How do I contact Nicole D. Perry?: The corporate mailing address for Ms. Perry and other Apellis Pharmaceuticals executives is 100 FIFTH AVENUE, WALTHAM MA, 02451. Apellis Pharmaceuticals can also be reached via phone at (617) 977-5700 and via email at [email protected]. Learn More on Nicole D. Perry's contact information.
Has Nicole D. Perry been buying or selling shares of Apellis Pharmaceuticals?: Nicole D. Perry has not been actively trading shares of Apellis Pharmaceuticals in the last ninety days. Most recently, Nicole D. Perry sold 1,000 shares of the business's stock in a transaction on Friday, June 11th. The shares were sold at an average price of $61.55, for a transaction totalling $61,550.00. Following the completion of the sale, the vice president now directly owns 5,847 shares of the company's stock, valued at $359,882.85. Learn More on Nicole D. Perry's trading history.
Who are Apellis Pharmaceuticals' active insiders?: Apellis Pharmaceuticals' insider roster includes Caroline Baumal (Insider), Victoria Brown (Insider), James Chopas (CAO), Mark DeLong (SVP), Pascal Deschatelets (Insider), A. Dunlop (Director), Jeffrey Eisele (Insider), Cedric Francois (CEO), Federico Grossi (Insider), Karen Lewis (Insider), Alec Machiels (Director), Nur Nicholson (Insider), Nicole Perry (VP), Lukas Scheibler (Insider), Timothy Sullivan (CFO), Adam Townsend (Insider), and David Watson (General Counsel). Learn More on Apellis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Apellis Pharmaceuticals?: During the last twelve months, insiders at the sold shares 55 times. They sold a total of 832,985 shares worth more than $51,199,751.25. The most recent insider tranaction occured on April, 8th when insider Pascal Deschatelets sold 69,107 shares worth more than $3,743,526.19. Insiders at Apellis Pharmaceuticals own 7.5% of the company. Learn More about insider trades at Apellis Pharmaceuticals.
Information on this page was last updated on 4/8/2024.

Nicole D. Perry Insider Trading History at Apellis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/11/2021	Sell	1,000	$61.55	$61,550.00	5,847
6/1/2021	Sell	1,000	$56.40	$56,400.00	5,847
4/30/2021	Sell	1,000	$50.00	$50,000.00	5,847
2/9/2021	Sell	2,000	$50.00	$100,000.00	4,500
12/4/2020	Sell	18,000	$50.00	$900,000.00	18,000

Nicole D. Perry Buying and Selling Activity at Apellis Pharmaceuticals

Apellis Pharmaceuticals Company Overview

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Today's Range

Now: $47.53

$46.53

$48.19

50 Day Range

MA: $59.71

$47.51

$71.73

2 Week Range

Now: $47.53

$19.83

$94.75

Volume

1,175,455 shs

Average Volume

1,500,053 shs

Market Capitalization

$5.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88

Biden’s $374B Giveaway Into This Sector

From DTI | Ad

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story